Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Syncona

This page shows the latest Syncona news and features for those working in and with pharma, biotech and healthcare.

$450m diagnostics sale will fuel more Syncona biotech funding

$450m diagnostics sale will fuel more Syncona biotech funding

Radiopharmaceuticals firm sold to Braco Imaging. Syncona has sold off its innovative diagnostics company Blue Earth Imaging to Bracco Imaging for $450m (£354.3m). ... owner will continue to develop the business through its next chapter,” said Martin

Latest news

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    After a merger with fellow Syncona stablemate Orbit, Soraya has taken on the R&D lead role, charged with developing and eventually gaining approval for its lead investigational gene therapy, GT005

  • European venture funding for the life science sector European venture funding for the life science sector

    New funds such as Oxford Sciences Innovation, Syncona (which listed at the start of the year and consequently increased its deployment capital) are likely to reinforce this trend going forward. ... The recent flotation of Syncona’s Nightstar

  • Pharma deals during January 2013 Pharma deals during January 2013

    First in this vein this year, the Wellcome Trust announced the investment of $200m initial capital into Syncona Partners LLP a new evergreen investment company. ... Syncona will make investments across healthcare – device, diagnostics and thera-peutics

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    team. Chris Hollowood, chairman of the board and chief investment office at Syncona, said: “We are extremely pleased to appoint Soraya and look forward to her leadership and extensive gene therapy

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Chris Hollowood, chairman of Freeline Therapeutics and chief investment officer of Syncona, said: “Anne is an extremely accomplished executive with extensive experience in building and leading teams and developing haematology and

  • Edward Hodgkin elected chair of UK biotech association Edward Hodgkin elected chair of UK biotech association

    Hodgkin is currently a partner at the Wellcome Trust's independent subsidiary Syncona Partners, where his role is to create and lead new life science ventures.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Parkinson’s disease: past, present and future
Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Quick links